Urbach Law advises Fairmed Healthcare and its majority shareholder Strides Pharma on a €10 Million Debt Facility

<p>On July 1, 2021, <a href="https://www.fair-med.com/" target="">Fairmed Healthcare AG</a> announced that it has raised €10 million in senior secured financing from <a href="https://www.dukeroyalty.com" target="">Duke Royalty Limited</a>. Fairmed was founded in 2012 and is based in Zug, Switzerland. The company offers high-quality generic prescription medicines, over-the-counter medicines, dermocosmetics and nutritional supplements in various EU countries. Fairmed is majority owned by Strides Pharma Global Pte Ltd, which in turn is a wholly owned subsidiary of <a href="https://www.strides.com" target="">Strides Pharma Science Limited</a>, a publicly traded corporation.&nbsp;Duke Royalty is listed on AIM and is a provider of alternative capital solutions to a diversified range of businesses in Europe and world-wide.</p><p>Urbach Law acted as transaction counsel for Fairmed Healthcare AG and Strides Pharma Global Pte Ltd. The Urbach Law team was led by partner Simon Urbach and included associates Amelie Hoffmann and Rezeda Maritz.</p><p>Further information on the background of the financing is available at the following link:<br></p><p>​<a href="https://www.londonstockexchange.com/news-article/DUKE/new-royalty-agreement-with-fairmed-healthcare-ag/15040569" target="">London Stock Exchange</a>​<br></p>